TECENTRIQ in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced
or mTNBC whose tumours have PD-L1 expression ≥1% and who have not received prior chemotherapy for metastatic disease1
AE, adverse event; HRQoL, health-related quality of life; mTNBC, metastatic triple-negative breast cancer; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free survival.
- TECENTRIQ Summary of Product Characteristics.
Date of preparation: September 2019.